Document is current
Any future updates will be listed below
-
Authors
Lleó, Alberto
Carmona-Iragui, Maria
Videla, Laura
Fernández, Susana
Benejam, Bessy
Pegueroles, Jordi
Barroeta, Isabel
Altuna, Miren
Valldeneu, Silvia
Xiao, Mei-Fang
Xu, Desheng
Núñez-Llaves, Raúl
Querol-Vilaseca, Marta
Sirisi, Sònia
Bejanin, Alexandre
Iulita, M. Florencia
Clarimón, Jordi
Blesa, Rafael
Worley, Paul
Alcolea, Daniel
Fortea, Juan
Belbin, Olivia https://orcid.org/0000-0002-6109-6371
-
Funding
Funding for this research was provided by:
Instituto de Salud Carlos III (PI18/00327, CP18/00011, PI17/01019)
Fundació la Marató de TV3 (20141210)
Agència de Gestió d’Ajuts Universitaris i de Recerca (2017 SGR 547)
Centro de Investigación Biomédica en Red Enfermedades Neurodegenerativas (Programa 1. Alzheimer's disease)
- License Information
-
More Information
Article History
Received: 17 March 2021
Accepted: 14 June 2021
First Online: 28 June 2021
Declarations
:
: The study (IIBSP-BMS-2018-103) was approved by the local ethics committee (Comité Ètic d’Investigació Clínica, Fundació de Gestió Sanitària de l’Hospital de la Santa Creu i Sant Pau) and was conducted in accordance with the Declaration of Helsinki. All participants gave their written informed consent to participate in the study.
: Not applicable.
: Drs Belbin, Lleó, Fortea, and Alcolea declare a filed patent application (WO2019175379 A1 Markers of synaptopathy in neurodegenerative disease) that includes the 9 synaptic proteins evaluated in this study. D.A. participated in advisory boards from Fujirebio-Europe and Roche Diagnostics and received speaker honoraria from Fujirebio-Europe, Nutricia and from Krka Farmacéutica S.L. J.F participated in advisory boards from AC-Immune and was consultant to Novartis. MX, DX and PW are co-founders of CogNext.
